ALTME — TME Pharma NV Cashflow Statement
0.000.00%
Last trade - 00:00- €1.24m
- -€1.46m
Annual cashflow statement for TME Pharma NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.86 | -10.4 | -14.5 | -15.1 | -6.73 |
| Depreciation | |||||
| Non-Cash Items | -3.1 | 4.76 | 1.6 | 3.61 | 1.52 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.371 | 0.363 | 0.407 | -0.72 | -0.561 |
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Taxes Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -4.29 | -5.22 | -12.4 | -12.1 | -5.63 |
| Capital Expenditures | -0.016 | -0.039 | -0.014 | -0.021 | -0.019 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | 0 | 0 | — | — |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.016 | -0.039 | -0.014 | -0.021 | -0.019 |
| Financing Cash Flow Items | -0.096 | -0.299 | -0.066 | -0.145 | 0.14 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.4 | 14.2 | 11.5 | 7.29 | 3.27 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.9 | 8.92 | -0.848 | -4.82 | -2.39 |